Company & Pipeline Overview
Founded in 2014 and headquartered in Cambridge, MA, Black Diamond Therapeutics specializes in precision oncology, developing what it calls “MasterKey” therapies for genetically defined tumors ([1]). Unlike traditional cancer drugs that target a single mutation, Black Diamond’s proprietary Mutation-Allostery-Pharmacology (MAP) platform is designed to identify families of oncogenic mutations and craft small-molecule inhibitors that can hit clusters of cancer-driving mutations with one drug ([3]) ([3]). The goal is to achieve broad mutation coverage (including treatment-resistant variants) while sparing wild-type proteins to minimize toxicity ([1]) ([3]).
The company’s flagship program is silevertinib (BDTX-1535), a fourth-generation EGFR inhibitor. Silevertinib is engineered to be brain-penetrant (important for brain metastases or primary brain tumors) and highly selective for mutant EGFR, avoiding activity on normal EGFR ([1]) ([4]). This candidate aims to address a significant unmet need in non-small cell lung cancer (NSCLC) patients with “non-classical” EGFR mutations – a subset of EGFR-positive lung cancers that do not respond well to standard therapy. Real-world data show these non-classical EGFR mutations (e.g. uncommon EGFR exon variants or resistance mutations) are present in ~20–30% of EGFR-mutated NSCLC cases ([5]). When such mutations are present (sometimes alongside classical EGFR mutations), patients often experience shorter responses to current drugs like osimertinib (Tagrisso) ([5]). Black Diamond’s silevertinib is distinguished as the most advanced 4th-generation EGFR tyrosine kinase inhibitor in development that can address the full spectrum of EGFR mutations – covering classical mutations, these non-classical variants, and the C797S resistance mutation that emerges after Tagrisso – all with a single oral therapy ([5]). In short, if successful, silevertinib could fill a critical gap for patients who currently have limited targeted options.
As of Q3 2025, BDTX-1535 is in Phase 2 testing for first-line treatment of NSCLC patients harboring non-classical EGFR mutations ([4]). The Phase 2 trial (n=43 patients) completed enrollment in mid-2025 ([4]). Black Diamond has guided that objective response rate (ORR) data, along with preliminary duration of response, are expected in Q4 2025 ([4]). Guggenheim analysts have set a high bar for this readout, anticipating that silevertinib’s broad mutation coverage and wild-type sparing design will yield approximately a 50% ORR and ~10-month median progression-free survival (mPFS) – outcomes that would validate the drug’s “best-in-class” potential ([1]). Meeting or exceeding these metrics could position Black Diamond to advance silevertinib into pivotal trials and possibly attract a larger development partner ([1]).
Notably, Black Diamond is already exploring partnership opportunities for silevertinib’s next steps ([4]). The company is pursuing a two-pronged strategy: on one hand, strategizing to accelerate pivotal development of silevertinib in both NSCLC and glioblastoma (an aggressive brain cancer where EGFR mutations also play a role), and on the other hand planning for regulatory discussions with the FDA in 1H 2026 regarding the path to first-line NSCLC approval once more mature Phase 2 data (like PFS) are available ([4]) ([4]). This suggests management is weighing all options – potentially a fast-track or single-arm approval route if data are compelling, versus a standard Phase 3 trial – and leaving room for a partner’s involvement in funding or co-development. Aside from NSCLC, silevertinib (BDTX-1535) is also in an early Phase 1 dose-escalation for glioblastoma (GBM), given its ability to cross the blood-brain barrier ([4]). Positive signals in GBM could open another indication, though this is at a formative stage.
While silevertinib now takes center stage, Black Diamond’s pipeline was recently streamlined to concentrate on this lead asset. The company’s secondary program BDTX-4933 – a small-molecule targeting a broad range of RAF and RAS mutations (implicated in various solid tumors) – was out-licensed to Servier, a global pharmaceutical firm, in March 2025 ([4]) ([6]). Under that deal, Servier paid $70 million upfront and committed up to $710 million in potential development and sales milestones, plus royalties, for global rights to BDTX-4933 ([6]) ([6]). BDTX-4933 was a Phase 1-ready candidate aimed at both RAS and RAF mutant tumors (including KRAS-mutant lung cancer), and Servier’s interest – reflected in the sizeable upfront payment – underscores the perceived promise of Black Diamond’s drug design approach ([6]) ([6]). For Black Diamond, this partnership was transformative: it provided non-dilutive capital (strengthening the balance sheet, as discussed below) and allowed the company to focus its resources on advancing silevertinib as its core value driver ([4]). In effect, Black Diamond has become a one-primary-asset company post-licensing, which has both upsides (singular focus and funding) and downsides (pipeline concentration risk) that we will explore.
Dividend Policy & Shareholder Returns
Black Diamond Therapeutics does not pay a dividend and has no history of distributing cash to shareholders. Like most development-stage biotech companies, BDTX has never generated positive earnings nor paid any dividends, instead reinvesting all capital into R&D and clinical programs. The company explicitly acknowledges this policy in its filings: “We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock” ([7]). This means investors seeking income or yield will not find it here – any potential return on BDTX is contingent on stock price appreciation, which in turn depends on the success of the company’s drug development efforts. Traditional REIT metrics like FFO/AFFO are not applicable in this context (BDTX has no recurring operating cash flows or real assets – it is funded by equity capital and partnership revenue). In summary, shareholder value for BDTX will come solely from capital gains if the company’s pipeline progresses, rather than from dividends or buybacks.
Financial Position & Leverage
Balance Sheet: Black Diamond’s financial position has improved significantly in 2025, thanks largely to the Servier licensing deal and cost-cutting measures. As of the end of Q2 2025, the company held $142.8 million in cash, cash equivalents and investments ([4]). This cash balance jumped from $98.6 million at year-end 2024 to $142.8M by June 2025 ([4]), reflecting the $70M upfront payment from Servier (minus operating expenses) and possibly some interest income. Management reports that at the current burn rate, this cash provides runway into Q4 2027 ([4]) – in other words, they have over two years of funding in hand for ongoing trials and operations. Importantly, Black Diamond was even net income positive in the first half of 2025 (reporting a $45.9M profit for the six months, versus a $38M loss in the prior-year period) due to the one-time licensing revenue ([4]) ([4]). This non-recurring income bolstered the company’s equity base and gives management breathing room to advance silevertinib without immediate financing pressure.
Leverage & Debt: Black Diamond has essentially no long-term debt on its books. The company has funded its operations through equity raises (including its IPO in 2020 and follow-on offerings) and collaboration income, rather than borrowing. Industry data shows BDTX’s Debt-to-Capital ratio is effectively 0%, with zero long-term debt recorded from 2019 through 2024 ([8]). Consistent with this, the company generates interest income (from its cash investments) rather than paying interest expense – for example, in Q2 2025 BDTX earned $1.1M in interest income, as opposed to having any interest costs ([4]). The absence of debt means no looming maturities or interest payments to worry about; it also means shareholders are not at risk of dilution from convertible debt or burdensome loan covenants at this time.
Peek Inside: What's in the AI War Game Plan?
- Six strategic, time-sensitive investments with buy ranges
- Special reports: The 100-Year-Old Money Machine, Coal's Comeback, The Fastest Gas
- Jeff Brown's urgent briefings and trade execution ideas
The flip side of zero leverage is that Black Diamond will rely on equity financing or partnerships to fund any major needs beyond its current cash runway. However, with cash projected to last until late 2027, management has a window to reach value-inflection milestones (like Phase 2 data and potentially initiation of Phase 3) without needing to tap capital markets imminently. This prudent cash position, combined with a leaner cost structure after an October 2024 restructuring, has reduced quarterly cash burn to about $9–10 million ([4]) (down from ~$15M a year prior). The restructuring involved workforce reductions and the pipeline narrowing (BDTX-4933 out-licensing), yielding a 44% reduction in operating expenses year-over-year ([4]). With R&D and G&A costs sharply lower – Q2 2025 R&D was $9.3M vs $12.6M in Q2 2024, and G&A was $4.1M vs $9.6M ([4]) – Black Diamond has positioned itself to weather delays or modest overruns in the near term. In summary, leverage is virtually nil and the company’s financial health looks stable for the next couple of years, barring unexpected developments. This conservative balance sheet is a strength, as it affords management flexibility in negotiating partnerships or funding pivotal trials from a position of solvency.
(Note: Since BDTX has no debt, traditional metrics like interest coverage or debt maturities are not applicable. The company’s “coverage” of fixed charges is not a concern given the lack of interest obligations. Instead, investors should monitor the cash burn rate vs. cash on hand, which as noted is manageable through 2027.)
Valuation & Analyst Outlook
Valuing a clinical-stage biotech like Black Diamond is inherently challenging, as standard metrics (P/E, P/FFO, etc.) are not meaningful for a pre-revenue company. Black Diamond currently has no product revenue (TTM revenue is $0) and continues to operate at a net loss (excluding one-time license payments) ([8]). As such, the stock’s valuation hinges on future potential – namely, the expected commercial value of silevertinib if it succeeds, and perhaps residual upside from the Servier-partnered program.
At the time of writing, BDTX trades around $6 per share, which gives a market capitalization of roughly $250–300 million ([8]). With ~$143M in cash on hand and no debt, the company’s enterprise value (EV) is on the order of $150–160 million. This EV represents what the market is currently assigning to Black Diamond’s pipeline and technology. One way to frame this: the market valuation is just about double the cash the company holds – indicating that investors are still cautious and heavily discounting the pipeline’s success probability. For context, Black Diamond’s book value (mostly cash) increased after the Servier deal, and the stock’s price-to-book hovers around 2x, which is relatively modest for a biotech with a late-Phase 2 asset (many peers trade higher on hope-value, though comparisons vary widely).
Analyst Price Targets: Despite the market’s cautious pricing, Wall Street analysts have issued bullish targets for BDTX, reflecting optimism about silevertinib’s prospects. Guggenheim’s recent $8 target (Buy rating) is one example – it implies well over 100% upside from early September levels ([1]). In fact, across several covering analysts, the average 12-month price target is about $10–11 per share, with published targets ranging from roughly $9 on the low end to $11.5 on the high end ([2]). According to Fintel data (as of Sept 3, 2025), the mean target of $10.46 represented a +264% premium to the stock’s then-price of $2.88 ([2]). Even after the stock’s recent rally (to ~$6), that consensus implies significant further upside. Analysts appear to be betting on a successful Phase 2 outcome and perhaps partnership or takeover scenarios. It’s worth noting that BDTX’s year-to-date return has already been strong – the stock was up nearly 40% more than the S&P 500 by mid-year ([1]) – suggesting that some positive expectation is priced in. Nonetheless, the gap between current price (~$6) and analyst targets (~$10+) indicates a valuation discrepancy: bulls see the stock as undervalued relative to its risk-adjusted prospects, while the market at large remains in “wait-and-see” mode ahead of clinical results.
Comparables: In the precision oncology space, valuations can swing dramatically on data readouts. To gauge BDTX’s valuation, one might consider the addressable market and precedent for EGFR-targeted therapies. AstraZeneca’s Tagrisso (the leading EGFR inhibitor for common mutations) achieved $5.8 billion in annual sales as of recent years ([9]), underscoring how lucrative the EGFR+ NSCLC market is. However, Tagrisso’s success is mostly in classical EGFR mutations – Black Diamond is initially targeting a smaller subset (non-classical mutants and resistant mutations). Still, if silevertinib proves effective across a broad spectrum (including eventually for resistance mutations post-Tagrisso), it could tap into a multi-billion dollar opportunity in aggregate. Small-cap biotech peers with late-stage targeted oncology drugs often trade at EVs in the few-hundred-million range pre-approval, similar to BDTX’s current EV. The Servier deal itself provides a valuation marker: Servier was willing to pay $70M upfront and potentially ~$780M total for BDTX-4933 ([6]), which was only in Phase 1. By contrast, BDTX’s market cap of ~$250–300M covers both silevertinib (Phase 2) and the future upside of 4933 (via milestones/royalties) – suggesting the stock is priced with a large risk discount. In other words, the market is taking a “prove it” stance: substantial value could be unlocked if Phase 2 results are strong, but until then BDTX’s valuation remains tempered.
Summary of Outlook: If silevertinib’s upcoming data impress (meeting the ORR and PFS benchmarks), we could see a reevaluation of BDTX’s price – potentially narrowing the gap to analysts’ targets. Additionally, a partnership deal for silevertinib (similar to the 4933 deal) could provide an objective valuation for that asset and inject new cash, which might boost the stock. On the flip side, any disappointment in the data or delays could reinforce the current low-multiple valuation or send the stock lower. For now, the risk/reward skew appears high: BDTX’s enterprise value is modest relative to its ultimate potential, but that’s because failure would leave little residual value (a binary profile common in biotech). Investors should ensure they are comfortable with this kind of valuation dynamic before taking a position.
Risks and Red Flags
Investing in Black Diamond Therapeutics entails significant risks, consistent with its profile as a clinical-stage biotech with a single lead program. Key risk factors include:
– Clinical and Regulatory Risk: The company’s fate hinges on the success of silevertinib’s clinical trials. There is no approved product yet – if the upcoming Phase 2 results fail to demonstrate compelling efficacy (e.g. if ORR or durability is well below expectations), BDTX’s main value driver could evaporate. Even with positive Phase 2 data, the path to regulatory approval is complex and uncertain. The FDA and other agencies may require larger controlled trials (e.g. a Phase 3 in a broader population) before approval, which would introduce more time, cost, and uncertainty. In sum, obtaining marketing approval is not guaranteed and can be impacted by factors out of the company’s control ([3]) ([3]). This binary clinical risk is the foremost concern – if silevertinib fails, Black Diamond has no other near-term assets to fall back on.
– Single-Asset Concentration: Following the out-licensing of BDTX-4933, Black Diamond is essentially a one-product company in the near term. This amplifies the impact of any problem with silevertinib. Many biotech peers try to diversify pipelines to spread risk, but BDTX is now fully concentrated on 1535/silevertinib. A clinical setback (safety issue, lackluster efficacy, etc.) would be a major blow. Likewise, the company’s MasterKey platform – while promising – has yet to produce multiple clinical successes, so its value is unproven beyond silevertinib. This concentration risk is a red flag: investors are betting almost entirely on one experiment.
– Competitive Landscape: Black Diamond operates in a highly competitive oncology market. Large pharmaceutical companies (AstraZeneca, J&J, Takeda, etc.) already have approved EGFR inhibitors or are developing next-gen EGFR drugs. For instance, J&J’s amivantamab (Rybrevant) and Takeda’s mobocertinib target a specific “non-classical” mutation (EGFR Exon20 insertion) in later-line NSCLC – demonstrating that big players are interested in the space. It’s feasible that competitors could develop their own broad-spectrum EGFR inhibitors or combinations that encroach on BDTX’s niche. Black Diamond will need to differentiate silevertinib and show clear benefits to gain adoption over established therapies ([3]). Additionally, if silevertinib eventually tries to move into classical EGFR mutant patients or earlier lines, it would face Tagrisso head-on, a daunting challenge given Tagrisso’s entrenched position. There are also potential intellectual property (IP) risks – the EGFR inhibitor field is well-patented (for example, AstraZeneca and Pfizer have litigated over EGFR drug IP ([10])), so BDTX must ensure it isn’t infringing existing patents and that its own patents are strong. Lastly, manufacturing and scalability could pose issues; making a highly selective, brain-penetrant drug at commercial scale might have complexities (though nothing public suggests a problem here, it’s a general risk noted in biotech). Overall, competition and external factors could limit Black Diamond’s ultimate market share even if its drug works ([3]).
– Financial and Dilution Risk: While Black Diamond’s current cash is sufficient for now, the company will likely require substantial additional funding to complete Phase 3 trials, regulatory filings, and (if approved) commercialization efforts beyond 2027 ([3]). If a strategic partnership is not secured on favorable terms, BDTX might need to return to the capital markets. Future equity offerings could dilute existing shareholders. Market conditions for biotech funding can be volatile – a downturn or trial setback could make fundraising difficult or only available at depressed valuations. Furthermore, the Servier deal, while lucrative in milestones, means Black Diamond gave up rights to 4933 – so if that program becomes a big success at Servier, BDTX will only receive milestone payments and royalties, potentially leaving value on the table. That deal also means BDTX can’t fall back on 4933 as an in-house plan B. In short, funding beyond 2027 is an open question and represents a risk if trials are delayed or more expensive than anticipated ([3]). On the flip side, the strong cash position through 2027 mitigates near-term insolvency risk – it’s the longer-term needs and dilution potential that investors should keep in mind.
– Execution and Other Risks: Even with good trial data, execution risk remains. Advancing from Phase 2 to pivotal Phase 3 (if required) is a big step – trial design, patient enrollment (especially for rare mutations), and regulatory alignment must be managed expertly. Any delays in trial enrollment or data analysis (for instance, if PFS data takes time to mature) could slow the momentum. Management’s ability to secure a partnership is also crucial; a failure to do so might signal that potential pharma partners see issues that investors don’t. Additionally, normal corporate risks apply: the loss of key personnel (scientists or executives), shifts in the regulatory environment, or unforeseen safety issues in a larger patient population. One red flag to note from the past: Black Diamond’s earlier lead candidate, BDTX-189, produced only modest efficacy in initial trials and was ultimately deprioritized in favor of BDTX-1535. This illustrates the unpredictability of drug development – even with a cutting-edge platform, not every candidate will succeed. While 1535 is more advanced and appears more potent, investors should be aware that past setbacks happened and could happen again. Finally, macro factors (e.g. healthcare policy changes, economic downturn affecting biotech funding, etc.) could indirectly pose risks, though these are harder to predict.
Despite these risks, no glaring red flags (such as fraud, regulatory sanctions, etc.) have emerged – the risks are fundamentally those of an early biotech: binary outcomes and high uncertainty. Black Diamond’s strategy of partnering one asset and focusing on another is rational, but it leaves a thin margin for error. Investors must be prepared for volatility around data announcements.
Open Questions & Future Outlook
As Black Diamond Therapeutics approaches its pivotal Phase 2 data release and beyond, several open questions remain unanswered. These uncertainties will shape the investment thesis going forward:
– Will silevertinib’s Phase 2 data hit the mark? The Q4 2025 readout will be the first real test of BDTX-1535’s efficacy in patients. Hitting the ~50% ORR and ~10-month PFS that Guggenheim and others anticipate ([1]) would strongly validate the drug. But what if ORR comes in lower (say 20–30%) or responses aren’t durable? It’s unclear if moderately positive (but not stellar) results would be enough for the FDA or for attracting a partner. How robust the data need to be for success is a key question. Investors will be watching not just binary response rate, but also safety/tolerability and activity in specific mutation subsets. This readout will essentially decide whether BDTX remains on a fast-track or faces significant regrouping.
– What regulatory path will the FDA allow? Black Diamond has indicated plans to meet with the FDA in the first half of 2026 to discuss a pivotal development path in 1L NSCLC ([4]). An open question is whether regulators might allow an accelerated approval based on the Phase 2 results (if they are outstanding) or whether a full randomized Phase 3 trial will be required. Given the unmet need in non-classical EGFR mutant patients (no approved targeted therapy specifically for them), it’s possible the FDA could be flexible. However, typically a control arm (e.g. vs chemotherapy or vs existing EGFR TKI off-label) might be expected for full approval. The outcome of regulatory discussions will determine timelines – could silevertinib reach the market in 2026–27 via an expedited route, or is it facing a longer trial process into 2028+? This remains an open point. Likewise, the design of any pivotal trial (population, endpoints, size) will depend on FDA feedback – something we’ll learn after those meetings.
– Will Black Diamond secure a development or commercial partner? The company is actively exploring partnerships for advancing silevertinib in both lung cancer and glioblastoma ([4]). A partnership (or even an acquisition by a larger pharma) could provide the resources and expertise to accelerate Phase 3 and commercialization. It’s uncertain when such a deal might occur, if at all. Some potential partners may be waiting to see the Phase 2 data before committing. If the data are strong, we might see a licensing or co-development agreement in 2026, potentially with significant upfront cash (analogous to the Servier deal) that could further de-risk BDTX’s finances. On the other hand, if no partnership materializes by the time Phase 3 starts, will Black Diamond attempt to go it alone? That would raise questions about operational capacity – a small company would have to scale up substantially (trial sites, manufacturing, regulatory prep) to run a Phase 3 and prepare for possible approval. Thus, a major open question is whether BDTX remains independent through development or aligns with a bigger player. The answer will influence its funding needs and strategic direction.
– How will Black Diamond finance late-stage development and beyond? Tied to the partnership question is the issue of funding. Current cash takes BDTX into late 2027 ([4]), which likely covers completing Phase 2 and maybe initiating Phase 3. But a full Phase 3 trial (especially global, if required) and preparation for commercialization would exceed the current budget. If no partner covers those costs, Black Diamond might need to raise capital around 2026–2027. An equity raise at significantly higher stock prices (if data are good) would be less dilutive and more feasible; however, if markets are risk-averse, even good companies can struggle to raise funds. Another angle: could Black Diamond monetize some of the Servier milestones or royalty (via a royalty financing) to bring in cash? Or might it license regional rights (e.g. to a Japanese or Chinese firm for Asia market) for upfront payments? These financing strategy questions are open – management’s moves in the next 1-2 years will be telling. The best case scenario for investors would be a non-dilutive infusion (from a partner or investor) post-Phase 2 that funds Phase 3, whereas the worst case would be a need to raise equity at a low valuation if the outlook is uncertain.
– What is the ultimate market opportunity and competition for silevertinib? Assuming silevertinib makes it to market, how big could it be? This depends on whether the drug’s label remains restricted to the “non-classical” EGFR mutant niche or if it expands into broader EGFR-mutant use (like for resistant mutations after Tagrisso failure, or even replacing first-line Tagrisso in some cases). An open question is will oncologists use silevertinib only where existing TKIs don’t work, or could it become a new standard of care? Answering this will require seeing more data: for example, does silevertinib work in patients who harbor both classical and non-classical mutations? Could it be combined with other therapies (like anti-EGFR antibodies or chemotherapy) to extend its reach? On the competitive front, one wonders if big pharma competitors are developing similar 4th-gen EGFR inhibitors. Black Diamond claims BDTX-1535 is the most advanced of its kind ([5]), but it’s possible others (perhaps in China or in academia) have compounds in earlier stages. If BDTX-1535 shows success, it could spark increased competition – for instance, another company might trial a combination of Tagrisso + another agent to cover non-classical mutations, or fast-track their own broad-spectrum EGFR drug. How Black Diamond will maintain an edge (through patents, fast execution, or superior data) is an open question that will play out over time.
– Are there other pipeline opportunities or is BDTX a one-shot story? With 4933 handed off to Servier, Black Diamond’s internal pipeline beyond silevertinib is currently thin. The company’s MAP platform in theory can generate additional candidates against other mutation clusters (perhaps in other oncogenes). An open question is whether management will re-invest in pipeline expansion (e.g. bringing a new preclinical candidate forward using its technology) or continue to focus solely on silevertinib until it’s further along. Investors may want to know if there’s a next program on the horizon (to diversify risk and leverage the platform). However, starting a new program would consume cash and bandwidth, so BDTX might hold off until after pivotal data or a partner is in place. Furthermore, Black Diamond could potentially gain from Servier’s advancement of BDTX-4933 – if Servier moves that into later-stage trials, milestones could flow in. The timing and likelihood of those milestone payments (up to $710M) is uncertain; typically, they might come at Phase 2 start, Phase 3 start, regulatory approval, etc. An open question is how much value (if any) should investors assign to those contingent milestones? It depends on Servier’s progress and success with 4933, which is out of BDTX’s control now. This dynamic is somewhat unique: BDTX could get a non-dilutive boost if Servier hits certain goals, but that’s a long-term and unpredictable tailwind.
In conclusion, Black Diamond Therapeutics offers a high-risk, high-reward profile as it heads into a crucial data release. Guggenheim’s $8 call and others’ bullish targets reflect optimism that the company’s MasterKey approach will pay off in the form of a game-changing EGFR therapy ([1]) ([1]). The company’s solid cash position and recent partnership have reduced near-term financial stress, allowing management to focus on execution ([4]) ([6]). However, investors should remain vigilant: the coming Phase 2 results are a make-or-break moment, and numerous uncertainties about regulatory path, commercialization, and competitive dynamics persist. For now, BDTX is an intriguing story of precision oncology innovation with a relatively low valuation pricing in many risks – whether those risks dissipate or manifest will become clearer in the next 6-12 months. This makes BDTX a stock to watch closely (or to approach with caution, depending on one’s risk tolerance) as the saga of “Phase 2 Results Ahead!”* unfolds.
Sources: Black Diamond Therapeutics SEC filings and press releases; Q2 2025 financials and corporate update ([4]) ([4]); Guggenheim analyst commentary via InsiderMonkey ([1]) ([1]); Yahoo Finance and Zacks analyst summaries ([2]); BeyondSPX independent research analysis ([3]) ([3]); Servier licensing agreement details ([6]); Macrotrends financial data ([8]); and relevant industry news (e.g. Tagrisso sales) ([9]). All information is up to date as of September 2025.
Sources
- https://insidermonkey.com/blog/guggenheim-sets-8-price-target-as-black-diamond-therapeutics-inc-bdtx-prepares-phase-2-results-1609658/
- https://fintel.io/news/guggenheim-initiates-coverage-of-black-diamond-therapeutics-bdtx-with-buy-recommendation-556
- https://beyondspx.com/article/black-diamond-therapeutics-unlocking-value-through-precision-oncology-and-strategic-focus-bdtx
- https://stocktitan.net/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2025-financial-n6gpy2i6mx1j.html
- https://finance.yahoo.com/quote/BDTX/news/?fr=sycsrp_catchall%2F
- https://globenewswire.com/news-release/2025/03/19/3045227/0/en/Servier-and-Black-Diamond-Therapeutics-Announce-Global-Licensing-Agreement-for-BDTX-4933-A-Targeted-Oncology-Therapy.html
- https://sec.gov/Archives/edgar/data/1701541/000170154120000032/bdtx-20200930.htm
- https://macrotrends.net/stocks/charts/BDTX/black-diamond-therapeutics/long-term-debt-capital
- https://ft.com/content/b845e8ab-9cbc-482c-aa22-0b5c020be099
- https://reuters.com/legal/pfizer-wins-1075-million-astrazeneca-us-cancer-drug-patent-trial-2024-05-17/
For informational purposes only; not investment advice.